← Oncology Approval Tracker

FDA DECISION ·

Zynyz

retifanlimab-dlwr · Incyte

Traditional approvalTraditional conversionMerkel cell carcinoma
Open LinkedIn brief ↓

1 min read · estimated

Sources

APPROVED USE

What FDA approved

For adults with metastatic or recurrent locally advanced Merkel cell carcinoma.

LAMPGEN ANALYSIS

Why it matters

FDA records traditional approval of the original 2023 accelerated Merkel cell indication, distinct from the 2025 anal cancer uses.

What research teams should watch

Preserve the Merkel cell evidence and label as a separate line in the indication tracker and route referrals through the rare skin tumor service.

PRIMARY RECORDS

Sources